You are viewing: US Humanized Mouse and Rat Model Market analysis

The US Humanized Mouse and Rat Model Market was valued at $87.6 Million in 2025 and projected to reach to $133.3 Million by 2030, representing a compound annual growth rate of 8.8%. The US humanized mouse and rat model market is poised for sustained growth through 2030, driven by increased R&D spending from major pharmaceutical companies headquartered in America and expanding academic research initiatives.

US Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Humanized Mouse and Rat Model Market Trends and Insights

  • This expansion reflects the US's dominant position in biomedical research and drug development, where humanized animal models serve as essential tools for understanding human disease mechanisms and evaluating therapeutic efficacy.
  • The US market benefits from substantial investment in pharmaceutical R&D, advanced research infrastructure, and a robust regulatory framework that mandates rigorous preclinical testing. Driving growth in the US market are increasing adoption of personalized medicine approaches, rising demand for more predictive in vivo models, and growing collaboration between academic institutions and pharmaceutical companies.
  • The US pharmaceutical and biotechnology sectors continue to prioritize humanized models to reduce clinical trial failures and accelerate time-to-market for novel therapeutics.
  • With an 8.8% compound annual growth rate through 2030, the US market demonstrates strong momentum as researchers seek improved alternatives to traditional animal models that better replicate human biology and disease pathology..

Key Market Statistics

  • CAGR (2025-2030) 8.8% CAGR
  • Market Size, 2025 ~USD 87.6 Million
  • Forecast, 2030 ~USD 133.3 Million
  • Country US

US Humanized Mouse and Rat Model Market Overview

Market Valuation :

The US humanized mouse and rat model market is valued at $87.6 million in 2025, with projections reaching $133.3 million by 2030, representing a robust 8.8% CAGR specific to the American market.

US Research Leadership :

The United States maintains the world's largest biomedical research infrastructure, with NIH funding and private pharmaceutical investments driving demand for advanced humanized animal models in preclinical studies.

Drug Development Pipeline :

US pharmaceutical and biotechnology companies rely heavily on humanized models for FDA-compliant drug development, making these models integral to the nation's competitive advantage in global drug discovery.

Regulatory Compliance :

FDA requirements for preclinical testing have increased adoption of humanized mouse and rat models across US research institutions, academic centers, and contract research organizations (CROs).

US Humanized Mouse and Rat Model Market Dynamics

  • The growing prevalence of complex diseases such as cancer, immunological disorders, and neurological conditions necessitates more sophisticated preclinical models that accurately replicate human biology.
  • Additionally, regulatory pressures from the FDA to reduce animal testing while improving predictive accuracy are accelerating adoption of humanized models.
  • Investment in biotechnology hubs across the US, particularly in California, Massachusetts, and North Carolina, will further propel market expansion as institutions seek cutting-edge research tools..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US humanized mouse and rat model market is valued at $87.6 million in 2025 and is projected to reach $133.3 million by 2030, representing an 8.8% CAGR.
    • The US market is driven by substantial pharmaceutical R&D investment, regulatory requirements for preclinical testing, and the country's leadership in biomedical innovation.
    • Increasing adoption of personalized medicine and demand for more predictive in vivo models are accelerating growth in the US market.
    • US pharmaceutical and biotechnology companies are leveraging humanized models to reduce clinical trial failures and improve drug development efficiency.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    US Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES14.414.715.616.617.618.619.620.65.8
    CROS AND CDMOS25.326.929.532.635.939.343.147.29.8
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES55.558.162.768.37479.986.2938.2
    TOTAL95.299.7107.8117.5127.4137.8148.9160.88.3

    Target Audience

    • US Pharmaceutical Companies : Major US pharma firms need detailed market intelligence to optimize preclinical research budgets, evaluate supplier capabilities, and accelerate drug development timelines using humanized models.
    • Biotechnology Startups : US biotech startups require market sizing and growth projections to secure venture funding, validate business models, and position humanized model offerings competitively within the American market.
    • Contract Research Organizations (CROs) : US-based CROs need market data to expand service portfolios, identify client demand trends, and justify investments in humanized model capabilities to support their pharmaceutical clients.
    • Academic Research Institutions : US universities and research centers use market insights to justify funding requests, benchmark their capabilities against peers, and identify collaboration opportunities with industry partners.
    • Medical Device & Diagnostic Companies : US medical device firms need market intelligence to understand humanized model applications in device testing, identify partnership opportunities with research institutions, and support regulatory submissions.

    Key Companies in the US Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • US Market-Specific Sizing : Obtain precise valuation data exclusive to the US market, including 2025 baseline ($87.6M) and 2030 forecast ($133.3M), enabling accurate budget allocation and investment decisions for American operations.
    • Regulatory Landscape Insights : Understand FDA compliance requirements and how they drive humanized model adoption across US research institutions, helping organizations align product development with American regulatory standards.
    • Competitive Positioning : Identify key US-based suppliers, CROs, and academic institutions dominating the humanized model space, allowing strategic partnerships and competitive benchmarking within the American market.
    • Growth Opportunity Analysis : Leverage the 8.8% CAGR specific to the US to identify high-growth segments, emerging applications, and geographic hotspots within major US biotech hubs for targeted expansion strategies.
    • Investment Decision Support : Make informed investment and acquisition decisions based on comprehensive US market data, including demand drivers, end-user preferences, and revenue forecasts through 2030.

    Frequently asked questions

    What is the current size of the US humanized mouse and rat model market?

    The US humanized mouse and rat model market was valued at $87.6 million in 2025 and is expected to grow to $133.3 million by 2030.

    What is the projected growth rate for the US market through 2030?

    The US market is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2030.

    Why is the US a dominant market for humanized animal models?

    The US leads in humanized model adoption due to its substantial pharmaceutical R&D investment, advanced research infrastructure, regulatory mandates for preclinical testing, and strong academic-industry collaboration.

    What factors are driving growth in the US humanized mouse and rat model market?

    Key growth drivers include increasing adoption of personalized medicine, rising demand for more predictive in vivo models, growing pharmaceutical R&D spending, and efforts to reduce clinical trial failures.

    How do humanized mouse and rat models benefit US drug development?

    Humanized models provide more accurate prediction of human drug responses, reduce clinical trial failures, accelerate time-to-market for therapeutics, and support the development of personalized medicine approaches in the US.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status